Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (233)	10/31/2002 11:37:31 AM
From: keokalani'nui	Read Replies (1) of 824

November 3 ASN: P2 IMN, 117 patients. 5g1.1 November 18 AHA (late breaker): P2 AMI, lytic and pci, 1800 pts. Pexelizumab. December 9 ASH (Oral): Eculizumab, a C5 Complement Blocking Antibody, Abolishes Hemolysis and Renders Hemolytic Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Transfusion Independent. 5g1.1. (This one sounds like it worked, but talk about an orphan indication!)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next